GRI Bio Will Present IPF Research Findings in Boston
Company executives are set to detail progress on a new pulmonary fibrosis treatment at the 10th IPF Summit.
Updated on Sept. 28, 2026 in Asthma
Live Poll
Will clinical developments successfully yield effective new treatments for idiopathic pulmonary fibrosis by 2027?
GRI Bio will present new research findings regarding its idiopathic pulmonary fibrosis treatment on September 30 and October 1, 2026. The presentations will occur in Boston at the 10th IPF Summit.
Why it matters
The research aims to address significant unmet medical needs for patients suffering from idiopathic pulmonary fibrosis. By utilizing immune modulation, the company seeks to target the underlying drivers of the disease.
GRI Bio maintains a library of over 500 proprietary compounds to support its development of GRI-0621, an oral retinoic acid receptor agonist. The company noted that it will require substantial additional capital to fund a future Phase 2b clinical trial.
The players
GRI Bio
This biotechnology firm specializes in immune modulation and is based in La Jolla, California.
Vipin Kumar
He serves as the Chief Scientific Officer of GRI Bio.
Marc Hertz
He is the Chief Executive Officer of GRI Bio.
The details
GRI Bio is developing GRI-0621 as a novel oral therapy for treating idiopathic pulmonary fibrosis. The development process relies on preclinical and translational research programs designed to modulate immune responses.
Timeline
The 10th IPF Summit runs from September 29 to October 1, 2026.
Vipin Kumar presents at the summit on September 30, 2026, at 2:00 PM ET.
Marc Hertz presents at the summit on October 1, 2026, at 1:30 PM ET.
The Big Picture
The 10th IPF Summit serves as a key venue for sharing recent clinical developments in fibrosis research. GRI Bio is utilizing this platform to showcase its progress within the wider community of idiopathic pulmonary fibrosis researchers.
The development of new oral treatments like GRI-0621 could eventually provide patients with more accessible options for managing idiopathic pulmonary fibrosis. However, the company noted that additional capital is required before a Phase 2b clinical trial can proceed.
The takeaway
Advancements in immune modulation represent a shift toward targeting the root causes of fibrosis rather than just symptom management. Patients and investors should monitor upcoming clinical trial updates as the company seeks necessary funding for further development.
What happens next
GRI Bio is scheduled to present findings on September 30 and October 1, 2026, at the 10th IPF Summit in Boston.
Further reading
For more information on the latest respiratory research, visit the Asthma section.
Live Poll
Will clinical developments successfully yield effective new treatments for idiopathic pulmonary fibrosis by 2027?
